Loading stock data…
INVA
$23.11+0.12 (+0.52%)
Market ClosedLast close May 1
Innoviva, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Innoviva, Inc. in the Healthcare sector is trading at $23.11. The stock is currently 8% below its 52-week high of $25.15, remaining 12.3% above its 200-day moving average. Technical signals show neutral RSI of 38 and bearish MACD signal, explaining why INVA maintains its current momentum and trend strength. The Whystock Score of 85/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 38) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$23.11
Potential Upside
162%
Whystock Fair Value$60.55
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, an...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.75B
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
7.12
Beta
Defensive asset. Lower volatility than the S&P 500.
0.40
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
3.30%
Volume
Today's trading volume
390,759
Recent News
3 Bargain-Cheap Small Caps Worth a Second Look
Three low P/E small-cap stocks offer distinct catalysts and upside potential as investors look ahead to a broader market rally
Analysts See This Pharma Stock Surging 60%; Eyes Fresh Entry
This drug stock has used recent declines as an opportunity to build a bullish base. Analysts see hearty price gains ahead.
Is It Time To Revisit Innoviva (INVA) After Strong Multi Year Share Price Gains
If you are wondering whether Innoviva's current share price still offers value, it helps to start by lining up the recent share performance against what the underlying business might be worth. At a last close of US$21.91, Innoviva's share price reflects a 1.1% decline over the past week and a 6.3% decline over the past month. Year to date, the stock shows a 10.3% return and a 26.4% return over the past year, 92.5% over three years and 80.6% over five years. These moves sit against a backdrop...
Mutiny At Aurinia Pharmaceuticals? Biotech Rallies On C-Suite Shake-Up
Aurinia Pharmaceuticals announced a complete overhaul of its C-suite on Monday, sparking both the biotech stock and hopes of an acquisition.
Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential
This clinical-stage biotech focuses on developing therapies for neurological and immunoscience disorders.